| Document |
Document Title |
|
WO/2019/092253A1 |
The present invention relates to an improved process of preparation of idelalisib using a solid form of intermediate of formula (2); characterized by XRPD pattern having 20 values 5.5°, 10.9°, 14.3°, 16.9° (±0.2) the process compris...
|
|
WO/2019/074822A1 |
The present invention provides compounds of formula (I), formula (II) or formula (III), wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicam...
|
|
WO/2019/051222A1 |
The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): --̅-̅-̅ is a single or double bond; n is an integer of 0 or 1; A is -CH2-, -CH(OH)-, or - C(O)-; G is C or N; X is -CH2-, O, or -C(O)-; Y is alkyl...
|
|
WO/2019/046931A1 |
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...
|
|
WO/2019/040109A1 |
Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates an...
|
|
WO/2019/036678A1 |
Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
|
|
WO/2019/031470A1 |
[Problem] The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. [Solution] The invention provides: a compound represented by formula (I) o...
|
|
WO/2019/032924A1 |
Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea c...
|
|
WO/2019/027941A1 |
The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.
|
|
WO/2019/026994A1 |
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...
|
|
WO/2019/002788A1 |
The invention relates to the use of ureas as extractants for fully or partially separating uranium(VI) from plutonium(IV) in an aqueous solution obtained by dissolving a spent nuclear fuel in nitric acid, by means of liquid-liquid extrac...
|
|
WO/2018/227300A1 |
Novel urea, thiourea and squaramide compounds and bioisosteres thereof of formulas (I) and (VI) and the use thereof for treating, attenuating, inhibiting or preventing inflammation and inflammation-related pathologies are described herein.
|
|
WO/2018/225663A1 |
The purpose of the present invention is to provide a recording material and a recording sheet, in each of which a non-phenolic compound having good color-developing performance and the like is used as a color developer. A compound repres...
|
|
WO/2018/219309A1 |
The present invention relates to a vinylarene derivative which modulates or inhibits the enzymatic activity of indoleamine 2,3-dioxygenase 1 (IDO-1), and the use thereof, and further relates to a vinylarene derivative and the use thereof...
|
|
WO/2018/211953A1 |
The purpose of the present invention is to provide a method for safely and efficiently producing a fluorinated carbonate derivative. This fluorinated carbonate derivative production method is characterized by emitting light in the presen...
|
|
WO/2018/212511A1 |
Provided are: a self-healing polymer network containing a physical crosslinker; and a composition therefor. The self-healing polymer network comprises self-healing monomers having a first polymerizable functional group and at least one u...
|
|
WO/2018/209030A1 |
The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the ...
|
|
WO/2018/189479A1 |
The present invention relates to conjugated polymers supporting chemical probes and the use thereof for the preparation of chemical sensors based on carbon nanotubes allowing the selective detection of analytes in the water.
|
|
WO/2018/187414A1 |
The present disclosure provides compounds and methods for inhibiting mTORC2, as well as methods for treating cancers such as glioblastoma.
|
|
WO/2018/181986A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/179343A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/172852A1 |
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...
|
|
WO/2018/168573A1 |
When recovering and utilizing the urea and NH3 contained in a gas that contains urea dust and NH3 and has been discharged from a urea granulation step, an aqueous urea solution to be fed to the urea granulation step is prevented from suf...
|
|
WO/2018/170109A1 |
The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins - mitoch...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/161033A1 |
Described herein are IRE1-alpha inhibitors, compositions containing such inhibitors, and methods of treatment of cancer that include administration of such compounds. Exemplary compounds are provided throughout the application.
|
|
WO/2018/154560A1 |
The invention provides aqueous hydrohalide liquid compositions containing more than 50% hydrohalide and less than 8% water. A method is provided for preparing a composition containing up to 95% urea hydrobromide, which is liquid at ambie...
|
|
WO/2018/148737A1 |
The present invention is directed to the use of a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of the symptoms of dementia with Lewy bodies, Parkinson's disease, or a combination thereof in an individual...
|
|
WO/2018/143492A1 |
The present invention relates to an aminobenzaldehyde derivative and an amino acid chiral extractant comprising the same, wherein the amino acid chiral extractant can allow amino acids in an aqueous solution to be extracted with high chi...
|
|
WO/2018/145021A1 |
The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compou...
|
|
WO/2018/133756A1 |
The present invention relates to a targeted autophagy agonist and an application thereof in the treatment of neurodegenerative diseases, pertaining to the technical field of pharmaceuticals for the treatment of neurodegenerative diseases...
|
|
WO/2018/096011A1 |
The invention relates to a method for alkylating an amino compound, characterized in that at least one triazine derivative of general formula (I) or at least one urea or urea derivative of the general formula (II), (II), wherein • R4 a...
|
|
WO/2018/087019A1 |
The invention relates to a method for producing amide bonds, particularly peptide bonds, with the aid of new amide coupling reagents containing an anion of formula (I); the invention also relates to these new reagents and to the producti...
|
|
WO/2018/080007A1 |
The present invention relates to a preparation method for removing triuret causing turbidity in urea water and to urea water prepared thereby and, more specifically, to a preparation method wherein urea is introduced to de-ionized water ...
|
|
WO/2017/031156A8 |
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymph...
|
|
WO/2018/066646A1 |
The present invention addresses the problem of finding a novel medicine which has an excellent tryptophanase inhibitory effect, suppresses indoxyl sulfate production in blood to thereby prevent deterioration of renal function, and thus c...
|
|
WO/2018/064559A1 |
The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose...
|
|
WO/2018/048862A1 |
The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.
|
|
WO/2018/048871A1 |
The present invention relates to a newly identified solvate form of (i?)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention furth...
|
|
WO/2016/153354A8 |
Disclosed is a method for the integrated production of two different urea products. One is an aqueous urea solution suitable for use in NOx abatement (generally indicated as Diesel Exhaust Fluid – DEF). The other is a solution used as ...
|
|
WO/2018/045229A1 |
The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
|
|
WO/2018/033525A1 |
This invention relates to compounds that are agonists or partial agonists of the histamine site of the NMDA receptor, the method of preparation thereof and applications thereof.
|
|
WO/2018/018091A1 |
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.
|
|
WO/2018/019987A1 |
The present invention relates to the medicinal use of small organic compounds, in particular amide and urea derivatives, for the treatment of congenital disorders of glycosylation, and in particular PMM2 congenital disorder of glycosylat...
|
|
WO/2018/007986A1 |
I n the process of the present invention, cariprazine is prepared by converting (trans-4-amino- cyclohexyl)-acetic acid ethyl ester hydrochloride to trans-4-aminocyclohexyl) acetic acid or its hydrochloride by hydrolysis, from the obtain...
|
|
WO/2018/005625A1 |
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula (I) or a pharmace...
|
|
WO/2017/188551A1 |
The present invention relates to a novel N-acylurea derivative and use thereof in the treatment or prevention of cardiovascular diseases and, more particularly, to a novel N-acylurea derivative, a pharmaceutical composition comprising th...
|
|
WO/2017/183723A1 |
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...
|
|
WO/2017/180323A1 |
The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide re...
|
|
WO/2017/172761A1 |
The present disclosure relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as modulators of the N-formyl peptide receptor (FPR), including FPRl a...
|
